Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
BioNTech partners with CEPI to advance development of mpox vaccine
- By Reuters
- Bengaluru
- Sep 19, 2023
Germany's BioNTech said on Monday it is entering into a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of its mpox vaccine.
CEPI will provide funding of up to $90 million to support the development of vaccine candidates which is based on BioNTech's mRNA technology. BioNTech will initiate a early-to-mid stage trial for the vaccine BNT166 for the prevention of mpox.
Mpox is a viral illness which causes skin rashes and can be transmitted to humans through physical contact.
The partnership is part of BioNTech's strategy to develop vaccines for the prevention of high-medical-need infectious diseases, including diseases that disproportionally affect lower-income countries, the company said.